VIVA Biotech Holdings has provided an update regarding the disposal of an equity interest in its subsidiary, VIVA Shanghai, to a group of institutional investors. According to the announcement, the investors, including HLC SPV, Qingdao Hongyi, Daxue Investments, True Light P, and Raed Capital Holdings 2 Ltd, hold minority shares in VIVA Shanghai as a result of a previous transaction. Under the terms of the Shareholders Agreement, these investors have the right to require VIVA Shanghai, VIVA Biotech Holdings, and related parties to repurchase their equity interest if VIVA Shanghai does not complete a qualified IPO or achieve a qualified merger and acquisition transaction by December 31, 2026. However, the investors have agreed to temporarily suspend their right to enforce the repurchase obligation during the period between December 31, 2026, and December 31, 2028, due to prevailing market conditions and ongoing business and capital raising plans for VIVA Shanghai. All other terms of the Shareholders Agreement remain in effect, and the company will provide further updates as appropriate.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. VIVA Biotech Holdings published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260105-11979660), on January 05, 2026, and is solely responsible for the information contained therein.